Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

NCT02275416 is registered in ClinicalTrials.gov with Ultimovacs ASA as lead sponsor.

NCT NCT02275416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02275416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Lead sponsor
Ultimovacs ASA
Phase
Phase 1/2
Overall status
Completed
Start date
February 2, 2015
Completion date
November 3, 2020
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma